Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL-EVOLVE in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
2024-517966-40-00Phase 2Authorised
- Sponsor
- Goethe University Frankfurt
- Start
- Jul 2023
- Modality
- Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ponatinib, imatinib and blinatumomab in acute lymphoblastic leukemia (ALL) (5 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Overall survival. Planned start Jul 2023; status: authorised.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-517966-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517966-40-00.